Naderian Ramtin, Eslami Majid, Ahmad Sajjad, Paraandavaji Elham, Yaghmayee Shayan, Soltanipur Masood, Naderian Rayan, Pajand Omid, Tajdini Parisa, Alizadeh Akram, Sanami Samira
Nervous System Stem Cells Research Center, Semnan University of Medical Sciences, Semnan, Iran.
Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
Rev Med Virol. 2025 May;35(3):e70035. doi: 10.1002/rmv.70035.
Both health and economic burdens of dengue virus (DENV), as an increasingly prevalent pathogen and global threat, exist in endemic regions. Vaccination is a key strategy in decreasing dengue morbidity and mortality. This systematic review assesses the efficacy, immune response and safety of dengue vaccines (Qdenga (TAK-003) and Dengvaxia (CYD-TDV)) in adolescents against the need for evidence-based data for dengue vaccination strategies. We performed a systematic search of six databases (Scopus, PubMed, Web of Science, Cochrane, clinical trials. gov, and MEDLINE) for studies published until October 2024. A total of 482 articles were identified, 32 studies met the inclusion criteria after removing duplicates and title and abstract screening. Immunogenicity and safety profiles for both vaccines. TAK-003 showed high seropositivity rates with all of the four DENV serotypes, especially for DENV-2, with sustained antibody responses 3 years after vaccination. CYD-TDV induced neutralising antibodies with balanced activity, but such an immune response was most efficient in individuals with baseline seropositivity, for whom greater efficacy was observed. Most adverse events were mild to moderate, such as transitory pain at the injection site and headache, while serious adverse events were rare and did not correlate with vaccination. Nonetheless, specific issues regarding serotype-unique efficacy variations and the threat of vaccine-induced immune enhancement in seronegative groups contribute to worry. These findings highlighted the importance of TAK-003 and CYD-TDV in reducing the impact of dengue, especially in endemic regions. Ongoing research is essential to refine vaccine deployment strategies, optimise protection across diverse populations, and address outstanding concerns regarding long-term immunity and safety in seronegative individuals.
登革病毒（DENV）作为一种日益流行的病原体和全球威胁，在流行地区带来了健康和经济负担。疫苗接种是降低登革热发病率和死亡率的关键策略。本系统评价评估了登革热疫苗（Qdenga（TAK-003）和Dengvaxia（CYD-TDV））在青少年中的疗效、免疫反应和安全性，以获取基于证据的数据用于登革热疫苗接种策略。我们对六个数据库（Scopus、PubMed、科学网、Cochrane、临床试验.gov和MEDLINE）进行了系统检索，查找截至2024年10月发表的研究。共识别出482篇文章，经过去除重复项以及标题和摘要筛选后，32项研究符合纳入标准。两种疫苗的免疫原性和安全性概况。TAK-003对所有四种DENV血清型均显示出高血清阳性率，尤其是对DENV-2，接种疫苗3年后抗体反应持续。CYD-TDV诱导具有平衡活性的中和抗体，但这种免疫反应在基线血清阳性的个体中最为有效，观察到这些个体有更高的疗效。大多数不良事件为轻度至中度，如注射部位短暂疼痛和头痛，而严重不良事件很少见且与疫苗接种无关。尽管如此，血清型特异性疗效差异以及血清阴性组中疫苗诱导免疫增强的威胁等特定问题令人担忧。这些发现凸显了TAK-003和CYD-TDV在减轻登革热影响方面的重要性，尤其是在流行地区。持续的研究对于完善疫苗部署策略、优化不同人群的保护以及解决血清阴性个体中长期免疫和安全性方面的突出问题至关重要。
